March 9, 2010 – The most recent data from 30 late-breaking clinical trials is being highlighted during the American College of Cardiology (ACC) 2010 scientific sessions, March 14-16 in Atlanta.
New this year are the “Trialist Is In” roundtable sessions, held 3:30-4:30 p.m. Sunday and Monday in Hall B2. These are meet-and-greet sessions with the physicians involved in the trials where attendees can ask questions in an informal setting,
This year’s ACC also includes many more overseas speakers than in the past. They will highlight device and trial information from studies abroad. James B. McClurken, M.D., chair of ACC.10, said ACC wants to expand the international influence and bring in new ideas and trial data.
“We are beginning to apply clinical information from trials from overseas here,” George Dangas, M.D., chair of the i2 Summit. He said the change reflects the trend of cardiology becoming more of an international community.
Dr. McClurken said it is difficult to predict which trials will have the most impact on cardiology, since the data has not yet been released. However, he is looking forward to data specifically from the EVEREST, NAVIGATOR, ACCORD and RACE trials.
The highly anticipated EVEREST trial compares percutaneous repair of mitral valve leakage to surgical repair, which will likely help chart the future direction of valve replacements. NAVIGATOR examines the reduction of cardiovascular events in diabetic patients. RACE examines heart rate control in atrial fibrillation patients. Several pharmacologic trials look at blood pressure and lipid control, and genomic response to warfarin treatment.
Other trials that are expected to yield new clinical insights include the STOP-AF trial of cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation, and a five-year follow-up of the PASSION Trial of paclitaxel-eluting stents vs. bare-metal stents.
Dr. Dangas expects some key findings regarding stent technology to come out of the third session’s interventional cardiology trials, bring presented at the 10:30 to noon session Monday, March 15.
The late-breaking trials will be presented in five sessions during ACC.
Trials of general interest in cardiology will be highlighted from 8-9:30 a.m. Sunday, March 14, in the Murphy Ballroom at the Georgia World Congress Center. The trials include:
• Effects of Combination Lipid Therapy on Cardiovascular Events in Type 2 Diabetes Mellitus: The ACCORD Lipid Study
• Effects of Intensive Blood Pressure Control on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial
• Rethinking Lower BP Goals for Diabetics With Documented Coronary Artery Disease: Findings From the INternational VErapamil SR - Trandolapril STudy (INVEST)
• The Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial
• Primary Safety and Efficacy Endpoints of the EVEREST II Randomized Clinical Trial
Trials involving cardiac arrhythmias are highlighted from 8-9:30 a.m. Monday, March 15, in the Murphy Ballroom. Trials include:
• Cryoballoon Ablation of Pulmonary Veins for Paroxysmal Atrial Fibrillation: First Results of the North American Arctic Front Stop-AF Clinical Trial
• Rate Control Efficacy in Permanent Atrial Fibrillation: a Comparison Between Lenient Versus Strict Rate Control in Patients With and Without Heart Failure. The RACE II Study
• The Impact of Remote Monitoring With Automatic Clinician Notifications on the Clinical Care of ICD and CRT-D Patients
• A Randomized Clinical Trial of Three Doses of a Long-Acting Oral Direct Factor Xa Inhibitor Betrixaban in Patients with Atrial Fibrillation
• Catheter Ablation vs. Antiarrhythmic Drug Therapy for Atrial Fibrillation: First Results of the CABANA Pilot Study
Interventional cardiology topics are covered in the third late-breaking trial session from 10:30 a.m. to noon Monday, March 15, in the Murphy Ballroom. Additional interventional cardiology topics will be covered in the fifth session of trial data on Tuesday. Studies on Monday include:
• Randomized All-Comer Comparison of Zotarolimus-Eluting and Sirolimus-Eluting Coronary Stents: 18-Month Follow-up in the SORT OUT III Trial
• Randomized Trial of a Polymer-Free Dual Drug-Eluting Stent Versus Polymer-Based Cypher and Endeavor Drug-Eluting Stents - Two-Year Clinical and Angiographic Outcomes
• First Report of the PERSEUS Randomized Controlled Trial Comparison of a Novel Platinum-Chromium, Thin-Strut TAXUS Element Stent Versus the TAXUS Express Stent in De Novo Coronary Stenoses
• Randomized Trial Evaluating the Efficacy of Cilostazol on Ischemic Vascular Complications After Drug-Eluting Stent Implantation for Coronary Heart Disease : Influence of Cilostazol-Based Triple Anti-Platelet Therapy on Ischemic Complication After Drug-Eluting Stent Implantation (CILON-T) Study
• Optimal Duration of Dual Anti-Platelet Therapy After Drug-Eluting Stents Implantation: A Randomized, Multicenter Trial
Additional late-breaking clinical trials are planned from 8-9:30 a.m. in the Murphy Ballroom. These trials include:
• Effect of Genotyping Warfarin Patients on Outcomes: Results From The National Community-Based Medco-Mayo Warfarin Effectiveness Study (MM-WES)
• The Diuretic Optimization Strategies Evaluation (DOSE) Study: A Randomized, Double Blind, Placebo-Controlled Trial Of Diuretic Strategies In Acute Decompensated Heart Failure
• Effect of the Direct Renin Inhibitor Aliskiren on Left Ventricular Remodeling Following Myocardial Infarction With Left Ventricular Dysfunction: ASPIRE
• Effects of Clinical Characteristics and Treatments on Gender Difference in Outcomes after Acute Myocardial Infarction: A Propensity Score-Matched Analysis
• Influence of Reduction of Left Ventricular Volume on Outcome After Coronary Artery Bypass Grafting With or Without Surgical Ventricular Reconstruction
Additional interventional cardiology trials will be covered from 10:30 a.m. to noon Tuesday, March 16, in the Murphy Ballroom. Trials include:
• Randomized Comparison of Angiojet Rheolytic Thrombectomy Before Direct Infarct Artery Stenting to Direct Stenting Alone in Patients with Acute Myocardial Infarction: the Jetstent Trial
• Long-term Outcome after Drug-Eluting Versus Bare-Metal Stent Implantation in Patients with ST-Elevation Myocardial Infarction. Three-year Follow-up of the DEDICATION Trial
• Five Year Follow-up After Primary Percutaneous Coronary Intervention With a Paclitaxel-Eluting Stent Versus a Bare-metal Stent in Acute ST-Segment Elevation Myocardial Infarction. A Follow-up Study Of The PASSION-Trial
• Ticagrelor Versus Clopidogrel In Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery: Results From The PLATO Trial
• A Randomized Trial Radial Artery Grafts versus Saphenous Vein Grafts in Coronary Artery Bypass Surgery: VA Cooperative Study
For more information: http://acc10.acc.org